Evidence map›Paper›PMID 32150085›Full record

ArticleMedicine2020

A randomized controlled trial for prevention of acute exacerbation of stable chronic obstructive pulmonary disease with acupoint application of traditional Chinese medicine: Study protocol clinical trial (SPIRIT Compliant).

Chuantao Zhang, Hongjing Yang, Wenfan Gan, Jun Chen, Yang Yang, Wei Xiao, Kunlan Long, Keling Chen, Qingsong Huang, Peiyang Gao

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. An Add-On Treatment for Moderate COPD with Squill-Oxymel (a Traditional Formulation fromEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Chuantao ZhangDepartment of Respiratory Medicine.
Hongjing YangDepartment of Respiratory Medicine.
Wenfan GanDepartment of Respiratory Medicine.
Jun ChenDepartment of Critical Care Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, PR China.
Yang YangDepartment of Respiratory Medicine.
Wei XiaoDepartment of Respiratory Medicine.
Kunlan LongDepartment of Critical Care Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, PR China.
Keling ChenDepartment of Respiratory Medicine.
Qingsong HuangDepartment of Respiratory Medicine.
Peiyang GaoDepartment of Critical Care Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, PR China.
National Patient Safety Foundation · USChengdu University of Traditional Chinese Medicine · CNS.P.E.C.I.E.S. · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChronic obstructive pulmonary disease (COPD) is a major public health problem that severely affects the quality of life of patients and may even endanger their lives. Although modern medicine has achieved significant results in relieving the clinical manifestations of COPD, it is difficult to prevent its progression and acute exacerbation entirely. As one of the classic aspects of acupuncture and moxibustion therapy, acupoint application of traditional Chinese medicine (TCM) can improve the clinical efficacy of western medicine in treating COPD. To date, however,there is no high-quality clinical trial to assess the effectiveness of TCM acupoint application directly in preventing acute exacerbation of stable COPD.

methodsThe study is a randomized, double-blind, placebo-controlled trial, in which 200 stable COPD patients will be randomly and equally divided into the experimental group or control group. Both groups will undergo standard Western medicine treatment; however, the patients in the experimental group will be also treated with TCM acupoint application, while the control group will be given placebo acupoint application. The duration of the treatment will be 1 month and a follow-up for 11 months. The primary outcome will be the number of acute exacerbation episodes of COPD, and the secondary outcomes will include the lung function, St George's Respiratory Questionnaire, COPD Assessment Test, and 6-Minute Walk Test. A safety assessment will also be performed during the trial. DISCUSSION: The aim of this study is to evaluate the efficacy and safety of TCM acupoint application in preventing acute exacerbation of stable COPD. Our study will provide sound evidence to support the evidence-based medicine of TCM acupoint application as an additional measure in the prevention of acute exacerbation of stable COPD.

trial registrationChiCTR1900026564, Registered 14 October, 2019.

Indexed as

Acupuncture PointsMedicine, Chinese TraditionalPulmonary Disease, Chronic ObstructiveAgedChinaDisease ProgressionDouble-Blind MethodFemaleHumansMaleMiddle AgedPlacebosProspective StudiesRandomized Controlled Trials as TopicSurveys and QuestionnairesTreatment OutcomePlacebos

Identifiers

PMID32150085
PMCPMC7478817
OpenAlexW3012441020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.